ORIGINAL RESEARCH article
Front. Med.
Sec. Hepatobiliary Diseases
PCSK9 Inhibitors Improve Lipid Profile and Hepatic Steatosis Surrogate Indicators in Patients with MAFLD and Type 2 Diabetes
Qingna Zhou 1,2,3
Xiaoxia Liu 1,2,3
Yunzhao Tang 1,2,3
Congqing Pan 1,2,3
Xuena Bi 4
1. NHC Key Lab of Hormones and Development, Tianjin, China
2. Tianjin Key Lab of Metabolic Diseases, Tianjin, China
3. Tianjin Medical University Chu Hsien-I Memorial Hospital & Institute of Endocrinology, Tianjin, China
4. Beichen Hospital of Nankai University, Tianjin, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Abstract
Objective To investigate the impact of proprotein convertase subtilisin kexin type-9 inhibitor (PCSK9i) on patients with metabolic dysfunction-associated fatty liver disease (MAFLD) combined with type 2 diabetes mellitus (T2DM). Methods This retrospective study reviewed the clinical data of 60 inpatients with MAFLD combined with T2DM from the electronic medical record (EMR) system. According to the medical records, all patients were categorized into the Control group (n=30, atorvastatin 20 mg QN) and the PCSK9i group (n=30, evolocumab injection 140 mg Q2W in addition to atorvastatin). Body mass index (BMI), glycemic control, hepatic fibrosis and steatosis surrogate indicators such as aspartate aminotransferase to platelet ratio index (APRI), fibrosis-4 index (FIB-4), fatty liver index (FLI) and controlled attenuation parameter (CAP), and lipid profiles, including total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), were analyzed at baseline and the 12-week follow-up in both groups. Multivariable regression analyses for changes in hepatic fibrosis and steatosis surrogate indicators were performed. Results At the 12-week follow-up, both groups exhibited significant reductions in lipid levels, with the PCSK9i group demonstrating greater decreases in TC (48.65% vs. 23.32%) and LDL-C (25.84% vs. 21.09%) compared to the Control group (P < 0.05). Meanwhile, the PCSK9i group exhibited significantly greater reductions in CAP (22.41% vs. 15.60%) and FLI (27.72% vs. 13.77%) in unadjusted analyses (both P < 0.05). Multivariable regression analyses demonstrated the superior improvement in CAP and FLI observed with PCSK9-i is independent of concomitant sodium-glucose co-transporter 2 inhibitor (SGLT-2i) therapy. Conclusion PCSK9i effectively reduced hepatic steatosis surrogate scores (FLI, CAP) and lipid levels (TC, LDL-C) in patients with MAFLD combined with T2DM.
Summary
Keywords
Metabolic dysfunction-associated fatty liver disease (MAFLD), Non-alcoholic fatty liver disease (NAFLD), Proprotein convertase subtilisin kexin type-9 inhibitor (PCSK9i), Sodium-glucose co-transporter 2 inhibitor (SGLT-2i), Type 2 diabetes mellitus (T2DM)
Received
29 November 2025
Accepted
17 February 2026
Copyright
© 2026 Zhou, Liu, Tang, Pan and Bi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Congqing Pan
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.